Your session is about to expire
← Back to Search
Dietary Supplement
OEA for Gulf War Syndrome
N/A
Waitlist Available
Led By Michael Hoffmann, MD
Research Sponsored by Roskamp Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights
Study Summary
This trial is studying OEA to see if it can help treat symptoms in people with Gulf War Illness.
Who is the study for?
This trial is for Gulf War veterans deployed between August 1990 and August 1991, up to age 70, who meet the CDC or Kansas definitions of GWI. Participants must be medically stable, not pregnant or nursing, willing to use birth control, and have no significant medical conditions that could affect the study.Check my eligibility
What is being tested?
The study tests Oleoylethanolamide (OEA) against a placebo in a double-blind setup where neither participants nor researchers know who's getting what. It aims to see how OEA affects blood lipid and immune markers in those with Gulf War Illness.See study design
What are the potential side effects?
While specific side effects are not listed here, potential risks may include reactions related to allergies or sensitivities to OEA or its components like olive oil and various excipients used in pill formulation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes in immune biomarker profiles
Changes in lipid biomarker profiles
Secondary outcome measures
Cognition
Changes in cognition (neuropsychological)
Changes in fatigue
+3 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: Study Supplement: OEAActive Control1 Intervention
26 subjects will take the supplement (oleoylethanolamide) during the first phase of the study. 200mg will be taken twice a day for the 10-week period in phase one.
Group II: ControlPlacebo Group1 Intervention
26 subjects will take the placebo during the first phase of the study (10 weeks).
Find a Location
Who is running the clinical trial?
Roskamp Institute Inc.Lead Sponsor
6 Previous Clinical Trials
474 Total Patients Enrolled
1 Trials studying Gulf War Syndrome
100 Patients Enrolled for Gulf War Syndrome
United States Department of DefenseFED
861 Previous Clinical Trials
227,142 Total Patients Enrolled
7 Trials studying Gulf War Syndrome
435 Patients Enrolled for Gulf War Syndrome
Michael Hoffmann, MDPrincipal InvestigatorThe Roskamp Institute
2 Previous Clinical Trials
152 Total Patients Enrolled
1 Trials studying Gulf War Syndrome
100 Patients Enrolled for Gulf War Syndrome
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with chronic multisymptom illness (CMI) according to the CDC or Kansas guidelines.You have been taking any dietary supplements that contain OEA within the past month.
Research Study Groups:
This trial has the following groups:- Group 1: Study Supplement: OEA
- Group 2: Control
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What results are researchers seeking from this investigation?
"This 10-week clinical trial seeks to measure changes in lipid biomarker profiles as its primary outcome. Secondary objectives involve examining any alterations in cognition (as measured by the CNS Vital Signs computerized neurocognitive assessment software), pain levels (using McGill Pain Questionnaire SF-MPQ) and quality of life (by Quality of Life Scale SF36)."
Answered by AI
How many participants is this experiment accommodating?
"Affirmative. According to data hosted on clinicaltrials.gov, this is still an active recruiting trial that was initially posted on June 10th 2021 and most recently updated on February 14th 2022. The study involves 52 patients from a single medical site."
Answered by AI
Are there still positions available to participants in this experiment?
"Indeed, this research is still recruiting participants. As per the information on clinicaltrials.gov, the trial was advertised on June 10th 2021 and its details were last updated February 14th 2022."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger